EA036112B1 - 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2 - Google Patents

7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2

Info

Publication number
EA036112B1
EA036112B1 EA201991161A EA201991161A EA036112B1 EA 036112 B1 EA036112 B1 EA 036112B1 EA 201991161 A EA201991161 A EA 201991161A EA 201991161 A EA201991161 A EA 201991161A EA 036112 B1 EA036112 B1 EA 036112B1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenylethylamino
pyrimido
oxazin
compounds
mutant idh1
Prior art date
Application number
EA201991161A
Other languages
English (en)
Other versions
EA201991161A1 (ru
Inventor
Ренато Алехандро Бауэр
Серж Луи Буле
Тимоти Пол Беркхолдер
Реймонд Гилмор
Патрик Джеймс Хан
Зоран Ранкович
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201991161A1 publication Critical patent/EA201991161A1/ru
Publication of EA036112B1 publication Critical patent/EA036112B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Предложены соединение, такое как определено в настоящем документе, или фармацевтическая композиция, содержащая соединение, для применения в лечении рака, включающего мутантную IDH1 или мутантную IDH2, имеющее структуру
EA201991161A 2016-12-16 2017-12-08 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2 EA036112B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16
PCT/US2017/065246 WO2018111707A1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Publications (2)

Publication Number Publication Date
EA201991161A1 EA201991161A1 (ru) 2019-11-29
EA036112B1 true EA036112B1 (ru) 2020-09-29

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991161A EA036112B1 (ru) 2016-12-16 2017-12-08 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2

Country Status (37)

Country Link
US (3) US11001596B2 (ru)
EP (2) EP3555105B1 (ru)
JP (1) JP6793836B2 (ru)
KR (1) KR102276022B1 (ru)
CN (2) CN115109075B (ru)
AU (2) AU2017378060B2 (ru)
CA (1) CA3045303C (ru)
CL (1) CL2019001551A1 (ru)
CO (1) CO2019005287A2 (ru)
CR (1) CR20190252A (ru)
CY (1) CY1123577T1 (ru)
DK (1) DK3555105T3 (ru)
DO (1) DOP2019000163A (ru)
EA (1) EA036112B1 (ru)
EC (1) ECSP19042682A (ru)
ES (2) ES2941631T3 (ru)
HR (1) HRP20201882T1 (ru)
HU (1) HUE052067T2 (ru)
IL (1) IL267236B (ru)
JO (1) JOP20190142B1 (ru)
LT (1) LT3555105T (ru)
MA (2) MA47399B1 (ru)
MD (1) MD3555105T2 (ru)
MX (1) MX385562B (ru)
MY (1) MY197313A (ru)
NZ (1) NZ754115A (ru)
PE (1) PE20190977A1 (ru)
PH (1) PH12019501328B1 (ru)
PL (1) PL3555105T3 (ru)
PT (1) PT3555105T (ru)
RS (1) RS61108B1 (ru)
SA (1) SA519401897B1 (ru)
SI (1) SI3555105T1 (ru)
TN (1) TN2019000158A1 (ru)
UA (1) UA123640C2 (ru)
WO (1) WO2018111707A1 (ru)
ZA (1) ZA201903125B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194383B1 (en) 2014-09-19 2019-11-06 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
MA53352A (fr) 2014-09-19 2021-09-15 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317327B9 (en) 2014-09-19 2020-04-09 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EP3640251B1 (en) 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
ES2941631T3 (es) * 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PL3494116T3 (pl) 2017-01-30 2020-04-30 Astrazeneca Ab Modulatory receptora estrogenowego
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CN115038700B (zh) * 2019-11-08 2025-07-25 内尔维亚诺医疗科学公司 偕二取代的杂环化合物及其作为idh抑制剂的用途
MX2022011846A (es) * 2020-03-23 2023-01-04 Lilly Co Eli Metodo para el tratamiento de sujetos resistentes al inhibidor idh1.
CN115443137B (zh) * 2020-03-23 2024-05-31 伊莱利利公司 使用突变idh抑制剂和bcl-2抑制剂的组合疗法
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
MX2022013391A (es) 2020-04-24 2022-11-30 Astrazeneca Ab Pauta posologica para el tratamiento del cancer.
US12559505B2 (en) 2020-06-28 2026-02-24 Wigen Biomedicine Technology (shanghai) Co., Ltd. IDH mutant inhibitor and use thereof
WO2022020281A1 (en) 2020-07-20 2022-01-27 Eli Lilly And Company Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
US20240261294A1 (en) * 2021-06-09 2024-08-08 Eli Lilly And Company Method for treating idh inhibitor-resistant subjects
CA3217608A1 (en) 2021-06-15 2022-12-22 Yuli Xie Idh mutant inhibitor and use thereof
US11746115B2 (en) 2021-08-13 2023-09-05 Eli Lilly And Company Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016171755A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) * 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
WO2017213910A1 (en) * 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014229283B2 (en) * 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN107405687A (zh) * 2015-04-24 2017-11-28 哈利伯顿能源服务公司 制作陶瓷或金属间化合物零件的方法
ES2941631T3 (es) * 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016171755A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) * 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
WO2017213910A1 (en) * 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors

Also Published As

Publication number Publication date
JP2020502157A (ja) 2020-01-23
EP3555105A1 (en) 2019-10-23
JOP20190142B1 (ar) 2023-03-28
ZA201903125B (en) 2024-08-28
PH12019501328A1 (en) 2020-02-24
CL2019001551A1 (es) 2019-10-25
HUE052067T2 (hu) 2021-04-28
WO2018111707A1 (en) 2018-06-21
CR20190252A (es) 2019-08-26
DOP2019000163A (es) 2019-07-15
PH12019501328B1 (en) 2023-05-12
ECSP19042682A (es) 2019-06-30
KR102276022B1 (ko) 2021-07-13
SA519401897B1 (ar) 2022-07-28
EP3763717B1 (en) 2023-03-08
US11629156B2 (en) 2023-04-18
JOP20190142A1 (ar) 2019-06-13
JP6793836B2 (ja) 2020-12-02
AU2017378060B2 (en) 2020-09-03
ES2835281T3 (es) 2021-06-22
LT3555105T (lt) 2021-01-11
MA47399B1 (fr) 2021-02-26
MD3555105T2 (ro) 2021-01-31
IL267236B (en) 2020-08-31
HRP20201882T1 (hr) 2021-01-22
CY1123577T1 (el) 2022-03-24
UA123640C2 (uk) 2021-05-05
ES2941631T3 (es) 2023-05-24
AU2020260493A1 (en) 2020-11-26
MX385562B (es) 2025-03-18
CN110072867A (zh) 2019-07-30
CN115109075A (zh) 2022-09-27
RS61108B1 (sr) 2020-12-31
MA53881A (fr) 2022-04-27
PE20190977A1 (es) 2019-07-09
US20200079791A1 (en) 2020-03-12
TN2019000158A1 (en) 2020-10-05
CO2019005287A2 (es) 2019-05-31
MA47399A (fr) 2019-10-23
EP3555105B1 (en) 2020-10-28
US20210230185A1 (en) 2021-07-29
MX2019006830A (es) 2019-08-22
CA3045303A1 (en) 2018-06-21
CN110072867B (zh) 2022-07-08
NZ754115A (en) 2021-07-30
CA3045303C (en) 2022-05-17
PL3555105T3 (pl) 2021-05-17
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
SI3555105T1 (sl) 2020-12-31
KR20190077539A (ko) 2019-07-03
MY197313A (en) 2023-06-13
EA201991161A1 (ru) 2019-11-29
IL267236A (en) 2019-08-29
BR112019009648A2 (pt) 2019-09-10
AU2020260493B2 (en) 2021-09-09
EP3763717A1 (en) 2021-01-13
DK3555105T3 (da) 2020-11-09
CN115109075B (zh) 2024-09-20
US11649247B2 (en) 2023-05-16
PT3555105T (pt) 2020-12-21
AU2017378060A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
SA519401897B1 (ar) [4، 5-d][1،3] 4h مركبات 7-فينيل إيثيل أمينو--بيريميدو أكسازين-2-ون كمثبطات أيزو سيترات ديهيدروجيناز 1 وأيزو سيترات ديهيدروجيناز 2 الطافر
GEP20237506B (en) Pcsk9 antagonist compounds
MX2009013625A (es) Compuestos de di (arilamino) arilo.
MX2018004832A (es) Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
CR20140388A (es) Compuestos terapeuticamente activos y sus métodos de uso
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
EP4309732A3 (en) Modulators of pcsk9 expression
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12015501036A1 (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
TH1901003646A (th) สารประกอบ 7-เฟนิลเอธิลอะมิโน-4h-พิริมิโด[4,5-d] 1,3-ออกซะซิน-2-โอน ในฐานะเป็นตัวยับยั้ง idh1 และ idh2 ที่กลายพันธุ์

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG TJ TM